Results · Apr-Jun 2026
Ajanta Pharma Q1 FY27 results
Sales grew 25% to ₹1,626 crore from ₹1,303 crore in Apr-Jun 2025.
Operating profit grew 21% to ₹424 crore, an operating margin of 26.1% (down 0.9 points from a year ago).
Net profit grew 31% to ₹334 crore from ₹255 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +14%, net profit +25%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 1,626 | 1,303 | +25% |
| Operating profit (EBITDA) | 423.6 | 351.4 | +21% |
| Operating margin | 26.1% | 27.0% | −0.9 pts |
| Net profit | 334.2 | 255.3 | +31% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.